Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): A multicentre, randomised, phase 3 trial Journal Article

   

Authors:	Safran, H. P.; Winter, K.; Ilson, D. H.; Wigle, D; DiPetrillo, T; Haddock, M .; Hong, T. S.; Leichman, L. P.; Rajdev, L.; Resnick, M.; Kachnic, L. A.; Seaward, S.; Mamon, H.; Diaz Pardo, D. A.; Anderson, C. M.; Shen, X.; Sharma, A. K.; Katz, A. W.; Salo, J.; Leonard, K. L.; Moughan, J.; Crane, C. H.
Article Title:	Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): A multicentre, randomised, phase 3 trial
Journal Title:	Lancet Oncology
Volume:	23
Issue:	2
ISSN:	1470-2045
Publisher:	Elsevier Science, Inc.
Date Published:	2022-02-01
Start Page:	259
End Page:	269
Language:	English
DOI:	10.1016/s1470-2045(21)00718-x
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
PUBMED:	35038433
PMCID:	PMC8903071
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=154950404&site=ehost-live
Notes:	Accession Number: 154950404 -- Entry Date: In Process -- Revision Date: 20220201 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 100957246. -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/192586